close
This ad will auto close in 10 seconds
'Govt needs to phase out branded drugs to promote generic medications'

'Govt needs to phase out branded drugs to promote generic medications'

Days after PM Modi's announcement, the Medical Council of India (MCI) had directed all the hospitals, doctors and state medical council to prescribe generic medicines to patients.

DNA: MCI cracks the whip on errant hospitals, doctors; directs them to prescribe generic drugs

DNA: MCI cracks the whip on errant hospitals, doctors; directs them to prescribe generic drugs

The implication of this directive is huge as India moves to mitigate healthcare costs across the nation.

MCI directs hospitals, doctors across India to prescribe generic medicines to patients

MCI directs hospitals, doctors across India to prescribe generic medicines to patients

This move comes few days after Prime Minister Narendra Modi urged at bringing a legal framework under which generic medicines should be given by the doctors and the healthcare system in India should have an extensive reach so that drugs are made available to all the people.

Generic drugs: Are they as effective as brand-name versions?

Generic drugs: Are they as effective as brand-name versions?

A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, safety, route of administration, quality, performance, intended use and risks.

Modi govt aims to break doctor-pharma company nexus, medicines will become cheaper

Modi govt aims to break doctor-pharma company nexus, medicines will become cheaper

We will bring in a legal framework by which if a doctor writes a prescription, he has to write in it that it will be enough for patients to buy generic medicine and he need not buy any other medicine, he said.

Germany suspends marketing of 54 drugs tested by India's GVK Bio

Germany suspends marketing of 54 drugs tested by India's GVK Bio

Germany has suspended marketing of 54 drugs tested by GVK Biosciences in compliance with the European Union's ban on around 700 generic drugs.

EU suspends sale of 700 generic drugs made in India

European Union nations have until August 20 to suspend the sale of some 700 generic drugs made in India, the EU`s executive confirmed on Monday.

Pharmexcil sees $1.2 billion export hit from EU ban

India's business loss arising from the European Union's ban on 700 generic drugs is likely to be around USD 1.2 billion, says industry body Pharmexcil.

Lupin, Cipla bid for UCB's US generic drugs portfolio: Report

Generic drugmakers Lupin Ltd and Cipla Ltdare among the companies bidding for top Belgian drugmaker UCB SA`s U.S. generic drugs business, a leading dailey reported on Monday, citing unnamed people with knowledge of the matter.

Endo to buy Par Pharmaceutical for $8.05 billion

Endo International will buy Par Pharmaceutical Holdings in a $8.05 billion deal that will strengthen Endo`s generic drugs business, the companies said Monday.

India may take WTO action against EU over drug clinical trials: GVK

The privately-held company, part of India`s infrastructure builder GVK Group, conducts clinical research for domestic and foreign drugmakers.

Novartis profits jump 12% on new drug sales

Novartis profits jump 12% on new drug sales

Swiss pharmaceuticals giant Novartis said Tuesday strong sales of new products helped push its net profit up 12 percent last year despite harsh competition from cheaper copycat generic drugs.

GVK Bio offers to re-do studies after EU ruling

Pharmaceutical research company GVK Biosciences has offered to re-do studies at its own cost after the European Union suspended marketing approval of some generic drugs due to alleged manipulation of data related to clinical trials.

France, Germany suspend some drug approvals over Indian data

All of the drugs being suspended, several of which are manufactured by Mylan Inc and Abbott , have brand name equivalents that can be used instead, so patients will not have to interrupt their treatment.

US court refuses Ranbaxy appeal to block ANDA nod for 2 drugs

Drug firm Ranbaxy Laboratories on Wednesday said the DC Federal Court in the US has not granted the company temporary restraining order to block the US health regulator from approving other ANDAs for generic versions of digestive disorder medicine Nexium and anti-viral Valcyte.

US denies Ranbaxy's bid to block launch of rival generics

A US court has denied a request by drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc`s heartburn pill Nexium and Roche`s antiviral, a court filing showed.

US court overturns bid by Ranbaxy to block launch of rival generic drugs

A US court has denied a request by drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc`s heartburn pill Nexium and Roche`s antiviral Valcyte.

Indian drugmakers see US sales hit by delay in new approvals

Leading Indian generic drugmakers Dr Reddy`s Laboratories Ltd and Glenmark Pharmaceuticals Ltd this month posted a drop in their second-quarter US sales

Lupin launches generic Ciprofloxacin in US market

The company had earlier received final approval for the product from the USFDA.

Wockhardt hit by another USFDA import restrictions

In a filing to the BSE, the company said it has received a warning letter from USFDA for its manufacturing units located at L1, Chikalthana, Aurangabad and B15, Waluj, Aurangabad.